Ontunisertib (AGMB-129)

About Agomab Therapeutics

Agomab Therapeutics is building a company focused on treating fibrosis by translating deep expertise in growth factor biology into a pipeline of modulating candidates. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function. The company's lead candidate, Ontunisertib (AGMB-129), is in Phase 1 development for fibrostenotic Crohn's disease, supported by a strong leadership team and recent IPO proceeds of approximately $200 million. Agomab's strategy combines internal scientific and development expertise with external partnerships to address pressing medical needs in fibrotic diseases.

Therapeutic Areas